Table 1.
Percentage binding of 125I labelled purified mAbs to different leukaemia/lymphoma cell lines
| mAbs | JOK1-5.3 | JOK1 | JURKAT | DAUDI | BL60.2 |
|---|---|---|---|---|---|
| anti-CD5 | 61.6 (+/- 2.3) | < 1% | 75.0 (+/- 1.8) | < 1% | < 1% |
| anti-CD71 | 47.2 (+/- 5.5) | n.d. | 50.6 (+/- 6.5) | 49.5 (+/- 2.6) | 50.0 (+/- 2.6) |
| anti-HLA DR | 56.1 (+/- 3.4) | 50.7 (+/- 6.71) | < 1% | 56.2 (+/- 13.0) | 63.4 (+/- 20.1) |
| anti-CD20 | 41.0 (+/- 3.4) | 40.8 (+/- 2.5) | > 1% | 31.1 (+/- 5.6) | 65.0 (+/- 6.2) |
The percentage of binding of each 125I-labelled mAb to increasing numbers of each target cell lines was measured. Results are expressed as % of specific binding extrapolated to an infinite number of target cells [44]